The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Biomarkers of response and resistance to antiangiogenic therapy
Open accessAbstract
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“no validated biomarkers are available to guide the use of antiangiogenic drugs7,126.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Cited by
Sorted by citations
Items 501–573 of 573
Microenvironnement du cancer de la prostate : structure, fonctions et applications thérapeutiques
Lorion, R., Bladou, F., Spatz, A., van Kempen, L. C. L. T., & Irani, J. (2016) · The French Journal of Urology · doi:10.1016/j.purol.2016.06.006 · Cited by 1
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_10 · Cited by 1
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_10-1 · Cited by 1
Shi, W., & Siemann, D. W. (2011) · Medical radiology · doi:10.1007/174_2011_260 · Cited by 1
Antiangiogenic Biotherapy and Chemotherapy in Breast Cancer: Review of Literature and Case Report
Sochor, M., & Chlebus, P. (2013) · Klinicka onkologie · doi:10.14735/amko201391 · Cited by 1
The Association Between Inflammation and Angiogenesis in Human Pancreatic Adenocarcinoma
Tănase, C., Necula, L. G., Neagu, A. I., & Albulescu, R. (2016) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-21-2-78 · Cited by 1
Silva, M. D., Yerby, B., Moriguchi, J., Gomez, A., Jun, H. T., Coxon, A., & Ungersma, S. E. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1065-y · Cited by 1
Vaccine Therapy in Pancreatic Cancer
Weinberg, B. A., & Pishvaian, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_16 · Cited by 1
Bitar, M. S. (2017) · Recent clinical techniques, results, and research in wounds · doi:10.1007/15695_2017_44 · Cited by 1
Abajo, A. (2014) · Deposito Adademico Digital Universidad De Navarra (University of Navarra)
Discovery and delivery of anti-angiogenic miRNAs for cancer treatment
Babae, N. (2013) · Utrecht University Repository (Utrecht University)
ANGIOGÊNESE E TUMORIGÊNESE: ONDE OCORRE A INTERSECÇÃO E AS POSSIBILIDADES DE TERAPIAS
de Oliveira, L. B. O., Gomes, C. F., Bampi, V. F., Rheingantz, M. G. T., & de Souza, M. A. L. (2010) · VITTALLE - Revista de Ciências da Saúde
Zhuang, G., & Ferrara, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_18
Lessons from Antiangiogenic Cancer Therapy–Induced Hypertension
Bursztyn, M. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12266
Zhu, A. X., Sahani, D. V., Duda, D. G., & Jain, R. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1173
Self-citationEarly clinical cancer trials: Proof of concept and beyond
Konings, I. R. H. M. (2011) · EUR Research Repository (Erasmus University Rotterdam)
Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways
Grépin, R., Guyot, M., & Pagès, G. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0466-8_20
Cummings, J. L., Ward, T. H., Dive, C., & Cummings, J. (2010)
Immunohistochemistry in the Study of Cancer Biomarkers for Oncology Drug Development
Jiang, F., & McKeegan, E. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-1516-3_5
Cardiotoxicity of Molecularly Targeted Chemotherapeutic Agents
Russell, K. S. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4441-0_27
Antiangiogenic therapies for malignant gliomas: new markers for targeted treatment
Biondi, A., Finocchiaro, G., & Cuppini, L. (2012)
Angiogenesis and anti-angiogenic treatments in colorectal cancer
Aktaş, S. H. (2014) · Turkish Journal of Oncology · doi:10.5505/tjoncol.2014.1066
Phase I trial of vinorelbine and sorafenib in metastatic breast cancer (MBC).
Luu, T. H., Frankel, P. H., Chung, C. T., Mortimer, J. E., Hurria, A., McNamra, M., Koehler, S., & Somlo, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13576
Aktaş, S. H., & Akbulut, H. (2014)
Les antiangiogéniques : limites actuelles en oncologie thoracique
Dansin, É., Lauridant, G., & Chahine, B. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1655
Pharmacokinetics and Pharmacogenetics of Metronomics
André, N., Ciccolini, J., Heng, M. A., & Pasquier, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_10
Coelho, A. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/bcms-4m26
Resistance to Angiokinase Inhibitors
Huang, Y. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_6
METRONOMIC CHEMOTHERAPY IN INOPERABLE CARCINOMA GALL BLADDER : OUR EXPERIENCE
Srivastava, V. P., Sharan, J., Kesarwani, R., & Prasad, T. (2015) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2015/554
Marseille, F. D. M. D. (2013)
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00014-7
Quantitative In Vivo Assessment of Tumour Vasculature-targeted Liposomes
Dunne, M. (2011) · TSpace (University of Toronto)
Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)
Bikfalvi, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-74376-9_16
Role of stromal Caveolin-1 in breast cancer angiogenesis
Sanchez, A. D. (2018) · doi:10.4321/repisalud.6730
Aleem, M., Sharma, D., Sharma, D., Dan, S., Gupta, P., Fakhri, K. U., & Rizvi, M. M. A. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch010
Application of a new 68Ga-labeled cNGR dimer peptide to microPET imaging of ovarian cancerPreprint
Yang, Y., Zhang, J., Zou, H., Shen, Y., & Wu, Y. (2020) · doi:10.21203/rs.3.rs-17734/v1
Development of Molecularly Targeted Agents in Early Phase Clinical Trials
Barata, P. C., & Yap, T. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_12
Faingold, D., Bakalian, S., & Russell-Hermanns, D. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3685-0_28
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017
Schirripa, M., Lenz, H., & Scherer, S. J. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_17-4
Duda, D. G. (2014) · Springer eBooks · doi:10.1007/978-3-642-27841-9_309-3
Self-citationDuda, D. G. (2014) · Springer eBooks · doi:10.1007/978-3-662-46875-3_309
Self-citationDuda, D. G. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_309
Self-citationSchirripa, M., Lenz, H., & Scherer, S. J. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_17
Hirschi, K. K. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.728776335.793562732
Gryazov, A. B. (2022) · Radiation Diagnostics Radiation Therapy · doi:10.37336/2707-0700-2022-2-1
Chae, S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2023) · doi:10.1158/1078-0432.c.6519216.v1
Self-citationYamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., & Tamura, T. (2023) · doi:10.1158/1078-0432.c.6519344.v1
Zhu, A. X., Duda, D. G., Ancukiewicz, M., di Tomaso, E., Clark, J. W., Miksad, R. A., Fuchs, C. S., Ryan, D. P., & Jain, R. K. (2023) · doi:10.1158/1078-0432.c.6518151
Self-citationYamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., & Tamura, T. (2023) · doi:10.1158/1078-0432.c.6519344
O’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2023) · doi:10.1158/1078-0432.c.6517882.v1
Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2023) · doi:10.1158/1078-0432.c.6519875.v1
Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2023) · doi:10.1158/1078-0432.c.6519875
Kazimova, T., Tschanz, F., Sharma, A., Telarović, I., Wachtel, M., Pedot, G., Schäfer, B. W., & Pruschy, M. N. (2023) · doi:10.1158/1541-7786.c.6545129.v1
Mireles, M., Jiménez-Valerio, G., Morales-Dalmau, J., Johansson, J., Martínez‐Lozano, M., Vidal-Rosas, E. E., Pérez, V. N., Busch, D. R., Casanovas, O., Durduran, T., et al. (2024) · Biomedical Optics Express · doi:10.1364/boe.532052
Advancement in therapeutic approach for treatment of metastatic colorectal cancer
Shreya, S., N, R. B., Kancharla, S., Kolli, P., Mandadapu, G., & Jena, M. K. (2025) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2025.033.2.22
Detecting vascular normalization in epithelial ovarian cancer
Mororó, J. D. S., Meira, D. D., Bizzo, S., Altoé, L. S. C., Casotti, M. C., Santana, G. M., Louro, L. S., Louro, T. E. S., Vicente, C. R., de Araújo, B. C., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02929-5
Open-Sourced Vessel Extraction Algorithm Using Structural Dissimilarity Mapping
Zhang, T., Liao, J., Feng, Z., Li, C., & Huang, Z. (2025) · IEEE International Ultrasonics Symposium · doi:10.1109/ius62464.2025.11201682
Shakibazad, N., Shahriari, M., & Ramzi, M. (2025) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.01809
Biomarkers of Response and Resistance to Anti-angiogenic Treatment
Duda, D. G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6467-5_15
Self-citationIntroduction to Endothelial Cell Pathophysiology and Angiogenesis
Giampietro, C., Dejana, E., & Claesson, L. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_2
Role of AI in molecular cancer pharmacology
Chawla, G., Gupta, O., & Pradhan, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00017-0
Alterations moleculaires au cours de la carcinogenese urotheliale vesicale
Pignot, G. (2011) · theses.fr (ABES) · doi:10.70675/f4f9879bzea61z4908z8214z4f04635306d7
Six‐Membered Heterocycles as VEGFR‐2 Kinase Inhibitors: A Structural and Therapeutic Review
Khalifa, M. M., Kadhim, T. K., Alaa, U., Hassan, R. Y., Khaldoon, A., Abass, Z. H., Ali, H. K. A., & Al‐Shibawi, Z. A. (2026) · ChemistrySelect · doi:10.1002/slct.73249
Smail, S. W., Flaih, A. H., Ismail, B. A., Ahmed, A. A., Bapir, A. A., Qadir, F. A., & Janson, C. (2026) · Immuno · doi:10.3390/immuno6020034
Sahu, M. R., Venu, A., Dasgupta, P., & Basu, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1818655
A cloud-based miniscope for neurosurveillance of brain health and disease in freely behaving animals
Senarathna, J., Yang, D., Brill, J., Das, S., Bare, S., Ren, Y., Vanness, D., Dinh, V., Karim, I., Banerjee, A. K., et al. (2026) · Nature Methods · doi:10.1038/s41592-026-03111-z
Thérapie génique de l'angiogenèse tumorale ciblée par des cellules endothéliales immatures
Collet, G. (2012) · theses.fr (ABES) · doi:10.70675/7e00daa0z60f1z4874za3c4zce11f3b40617
Metadata
- Authors
- Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
- Affiliations
- Harvard University (US)
- Duke Medical Center (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-06
- Volume
- 6
- Issue
- 6
- Pages
- 327-338
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC3057433
- OpenAlex
- W1993016882
- Cited by
- 572
- References
- 83
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
- National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
